Can a Triple-Drug cocktail turn inoperable liver cancer into a surgical target?
NCT ID NCT07738055
First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This trial is testing whether a combination of two newer drugs—envafolimab and suvemcitug—plus chemotherapy delivered directly to the liver can shrink advanced liver tumors enough to allow surgery. The study enrolls adults aged 18–75 with liver cancer that is currently too advanced for surgery. Participants receive three cycles of the combination, then doctors check if the tumors have shrunk enough for safe removal. The goal is to see if this approach can convert more cases to operable ones.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of envafolimab (an immunotherapy), suvemcitug (an anti-angiogenic drug), and HAIC (chemotherapy infused into the liver artery)
- What this could lead to
- If successful, this approach could help more patients with advanced liver cancer become eligible for surgery, potentially improving long-term outcomes.
- What could go wrong
- This is a small, early exploratory study with only 35 participants. The combination may cause serious side effects, and it is not yet known if it will effectively shrink tumors enough for surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POTENTIALLY RESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.